EsoGuard® / EsoCheck®
Detection of Barrett's Esophagus & Esophageal Precancer
Key Facts
About PAVmed
PAVmed is a diversified medtech company founded in 2014 by surgeons and an industry executive with an imperative to innovate across sectors. Its core strategy is a shared-services business model that provides centralized expertise to its portfolio of subsidiaries, aiming for efficient scale and de-risked commercialization. Current commercial momentum is driven by its subsidiaries Lucid Diagnostics, commercializing the EsoGuard® test for esophageal precancer, and Veris Health, focused on remote patient monitoring for oncology.
View full company profileAbout Lucid Diagnostics
Lucid Diagnostics is a commercial-stage company focused on preventing esophageal adenocarcinoma via early detection of precancerous Barrett's esophagus. Its core achievement is the commercial launch of the EsoGuard/EsoCheck system, a non-endoscopic diagnostic platform with FDA Breakthrough Device designation and established Medicare reimbursement. The company's strategy centers on penetrating the vast, under-screened GERD population through direct sales, strategic partnerships with fire departments, and inclusion in clinical guidelines to drive adoption.
View full company profile